"Quantitative immunity testing is key to confidently verifying whether a person has sufficient immunity against Covid-19," he said.
"It is well understood that high levels of antibodies against certain parts of viruses can rapidly neutralise and prevent infection; such antibodies are known as neutralising antibodies."
The company, led by renowned University of Auckland scientist Professor David Williams, had specifically targeted its tech at quickly quantifying these fast-acting antibodies.
"In the absence of verifying a person's immunity, it will be challenging for governments to have the confidence to reduce current border and travel restrictions."
Originally designed for use in animal health, the system was turned to Covid-19 antibody levels over the past year.
Ogilvie said it was now in its end stages and, while it required final phase studies and manufacture scale-up, the company aimed to roll out the system halfway through the year.
The company has proposed to the Government carrying out a 12-week trial with quarantining travellers to demonstrate its system could work at scale.
"We will also monitor those individuals to confirm that they do not develop the disease," he said.
In piloting it here, the Government could gain confidence in the tech, he said.
"Unlike other countries who are dealing with the 'here and now', New Zealand has the luxury to look into the future and adopt long-term sustainable solutions that will allow us to safely reopen our borders."
A Ministry of Health spokesperson said the tech appeared promising, but added that it had yet to be fully evaluated.
New Zealand currently wasn't considering point-of-care testing for Covid-19.
Idemia's Oceania managing director, Xavier Assouad, expected immunity screening to become a "crucial element" of the world resuming travel.
"As part of the innovation process, we are exploring an integration of the Orbis solution with Idemia's Mobile ID and border control platform - notably for risk assessment purposes."
